Synairgen shares jump on upbeat data from asthma drug study; Oxford BioMedica wins over investors with Parkinson's gene therapy;

 @FierceBiotech: Our most popular story today: Top 10 late-stage cancer drugs in 2012. Report | Follow @FierceBiotech

 @JohnCFierce: Merck KGaA still rather breezily talking about cuts again. No doubt continuing fallout from the cladribine fiasco. News | Follow @JohnCFierce

 @RyanMFierce: GAO report says the FDA's IT is behind the times. Not news to many of you, though. Article | Follow @RyanMFierce

> Shares of U.K. biotech Synairgen jumped almost 30% after the company disclosed mostly upbeat data from a Phase II study of its treatment SNG001 for stymieing infections in asthma patients. Article

> Biotech startups are trying new strategies to boost value for their brave investors, including organizing themselves as C corporations. Item (sub. req.)

> Oxford BioMedica has seen its shares soar because of the company's progress with an experimental gene therapy for Parkinson's disease. Report

Pharma News

 @FiercePharma: Merck KGaA plans to slash jobs in a socially responsible way. Article | Follow @FiercePharma

> EMA approves Novartis' Gilenya. Article

> Novo Nordisk, Public Citizen duke it out over Victoza. News

> China shuts down 10 drug capsulemakers. Story

> Reuters: Danone bids $11 billion for Pfizer baby formula business. News

> Docs go off-label more than 10% of the time. More

Medical Devices News

@FierceMedDev: Top 10 Medical Device R&D Budgets. Report | Follow @FierceMedDev

> emPower maker PixelOptics raises $7M. Story

> GI Dynamics' EndoBarrier implanted in first patients, stock soars. Article

> Olympus looks to push past scandal, but can it? More

> Feds seize Pharmaceutical Innovations' contaminated ultrasound gel. Item

And Finally… U.K. researchers have made more progress in the exciting field of synthetic biology, according to Bloomberg, which reported that their "artificial genetic material called XNA can be replicated in the test tube" in a similar way as the real thing. Report